In Vivo Cell Reprogramming

Genemagic’s in vivo cell reprogramming technology leverages AAV vectors to deliver reprogramming factors directly to glial cells, driving their transdifferentiation into specific neuronal subtypes. Through high-throughput screening, the company has identified and validated multiple reprogramming factor combinations. The current focus is on regenerating dopaminergic neurons in patients with Parkinson’s disease, aiming to address the root cause of neurodegeneration through in vivo cell replacement.

Epigenetic Editing Platform

Genemagic’s Epigenetic Editing Platform offers a novel approach to gene modification that differs fundamentally from traditional CRISPR-Cas9 or base editing. Unlike these methods, it does not induce double-strand DNA breaks, thereby avoiding chromosomal alterations while still achieving durable gene expression changes. This makes it a compelling therapeutic option for chronic diseases where long-term safety is critical, offering a safe, effective, and lasting alternative for genetic intervention.